Revenio Group Oyj - Financial Calendar

Revenio Group Corporation: Revenio Group's financial reporting and annual general meeting in 2018

Revenio Group Corporation, Stock Exchange Release, December 8, 2017 at 9:00


REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2018

During 2018, Revenio Group Corporation will publish the following financial
reports:

  * Financial Statements bulletin in regard to 2017 on Thursday, February
    15, 2018
  * Interim Report 1-3/2018 on Friday, April 20, 2018
  * Interim Report 1-6/2018 on Monday, August 6, 2018
  * Interim Report 1-9/2018 on Thursday, October 25, 2018

Due to an amendment in the Securities Market Act, which came into force on 26
November 2015, Revenio will publish the descriptive sections of its interim
reports for 1-3/2018 and 1-9/2018 in a concise form. The table sections will be
reported in accordance with previous practices.

The Annual General Meeting is planned to be held on Tuesday, March 20, 2018. The
Board of Directors will give a separate notice of the Annual General Meeting
later.

A shareholder, who wishes to place an item on the agenda of the Annual General
Meeting, shall submit the request in writing to the company's Board of Directors
by February 3, 2018. Such requests including the reasoning or a resolution
proposal can be submitted to the address: Revenio Group Corporation / Board of
Directors, Äyritie 22, FI-01510 Vantaa, Finland.

The Annual Report for 2017 will be published on the Group's website
www.revenio.fi during week 9 in 2018.

Revenio Group Corporation

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating margin
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.

[]